Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 6:44 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1969–1992 of 121,474 matching trials from the live ClinicalTrials.gov search.

Filters: Completed Clear all

Conditions: Energy, Cardiovascular Disease, Cancer
Interventions: 1.5PD, 3.0PD, control; Other
Lead sponsor: United States Department of Agriculture (USDA); Federal
Eligibility: 25 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Beltsville, Maryland

Conditions: Gardasil Vaccine, Stem Cell Transplant, Immunogenicity
Interventions: Gardasil; Biological
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Lung Cancer
Interventions: DNA analysis, DNA methylation analysis, RNA analysis, gene expression analysis, polymorphism analysis, laboratory biomarker analysis, medical chart review; Genetic · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 11
States / cities: Los Angeles, California • Lewes, Delaware • Newark, Delaware + 7 more

Conditions: Solid Tumors
Interventions: Ixazomib, Erlotinib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Inflammatory Breast Cancer, Male Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions: sunitinib malate, paclitaxel, doxorubicin hydrochloride, cyclophosphamide, filgrastim, therapeutic conventional surgery, laboratory biomarker analysis, flow cytometry; Drug · Biological · Procedure + 1 more
Lead sponsor: University of Washington; Other
Eligibility: Not listed
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 7
States / cities: Anchorage, Alaska • Tucson, Arizona • Boise, Idaho + 3 more

Conditions: Atrial Fibrillation
Interventions: General Anesthesia with endotracheal tube, General Anesthesia with laryngeal mask airway; Device
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Scarring
Interventions: Pinch Graft; Procedure
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Chronic Obstructive Pulmonary Disease, Aging
Interventions: Fiber Inulin, Placebo Maltodextrin; Dietary Supplement
Lead sponsor: Texas A&M University; Other
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: College Station, Texas

Conditions: Major Depressive Disorder
Interventions: Internet Cognitive Behavioral Therapy; Behavioral
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years to 45 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Atopic Dermatitis
Interventions: Etokimab, Placebo; Biological · Drug
Lead sponsor: AnaptysBio, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 37
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Encino, California + 34 more

Conditions: End Stage Renal Disease, Hemodialysis, Inflammatory Response, Cardiovascular Disease
Interventions: paricalcitol; Drug
Lead sponsor: Renal Research Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 3
States / cities: New York, New York

Conditions: Hemophilia, Hemophilia A, Hemophilia B, Hemophilia A With Inhibitor, Hemophilia B With Inhibitor, Haemophilia B Without Inhibitor, Haemophilia A Without Inhibitor, Haemophilia
Interventions: Not listed
Lead sponsor: American Thrombosis and Hemostasis Network; Network
Eligibility: 0 Years to 13 Years
Enrollment: 237 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 27
States / cities: Phoenix, Arizona • Madera, California • San Diego, California + 24 more

Conditions: Joint Disease, Pain, Acute, Pain, Chronic
Interventions: Cymbalta, Placebo; Drug · Other
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 25 Years to 75 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Atherosclerosis, Heart Failure, Congestive, Hypertension, Myocardial Infarction
Interventions: Angiotensin II type 1 receptor antagonists; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetes, Obesity
Interventions: Neomycin, Rifaximin; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hypoxia
Interventions: Diagnostic test of SPO2; Device
Lead sponsor: ChroniSense Medical Ltd.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Louisville, Colorado

Conditions: Depression, Anxiety
Interventions: Mindfulness Meditation, Psychoeducation; Behavioral · Other
Lead sponsor: University of South Dakota; Other
Eligibility: 18 Years to 64 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: Cataract
Interventions: Argos; Device
Lead sponsor: Shammas Eye Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 523 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 6
States / cities: Encino, California • Lynwood, California • Whittier, California + 3 more

Conditions: Tobacco Use Cessation, Smoking Cessation, Smoking, Tobacco Use Disorder
Interventions: Brief Intervention with NRT Initiation; Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 780 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Light-Chain Amyloidosis
Interventions: Ixazomib, Dexamethasone; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 6
States / cities: Boston, Massachusetts • Detroit, Michigan • Rochester, Minnesota + 2 more

Conditions: Hypertension
Interventions: Positive affect and self-affect induction; Behavioral
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004
U.S. locations: 1
States / cities: New York, New York

Conditions: Dengue
Interventions: Pre-transfection F17, Post-transfection F17, Post-transfection F19, Placebo; Biological · Other
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 45 Years
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: Interferon-gamma 1b; Drug
Lead sponsor: InterMune; Industry
Eligibility: 20 Years to 79 Years
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Ulcerative Colitis
Interventions: mesalamine; Drug
Lead sponsor: James Lewis; Other
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 8
States / cities: Naples, Florida • Winter Park, Florida • Atlanta, Georgia + 5 more

Search by objective public record fields.

Energy Value of Macronutrients From Pistachio Nuts and Mechanisms of Nutrient Action

Gardasil Vaccination in Post Stem Cell Transplant Patients

Study of Tissue Samples From Patients With Non-Small Cell Lung Cancer

Study of Ixazomib and Erlotinib in Solid Tumors

Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer

General Anesthesia With ETT vs LMA in Patients Undergoing Ablation for Atrial Fibrillation

Pinch Grafting Versus Second Intention Wound Healing for Mohs Micrographic Surgery Defects on the Scalp

Fiber Metabolism in Chronic Obstructive Pulmonary Disease

Internet Based Cognitive Behavioral Therapy Effects on Depressive Cognitions and Brain Function

Efficacy, Safety, and Pharmacokinetic Profile of Etokimab (ANB020) in Adult Participants With Moderate-to-Severe Atopic Dermatitis

Immune Effects of Vitamin D in Hemodialysis Patients

ATHN 8: Previously Untreated Patients (PUPs) Matter Study

Effect of Duloxetine on Opioid Use After Total Knee Arthroplasty

The Role of Angiotensin Type I Receptor in the Regulation of Human Coronary Vascular Function

Role of Methane in Glycemic Control

Polso SpO2 Accuracy Validation Study

Mindfulness-Based Interventions Targeting First-Generation College Student Retention in Rural Environments

Accuracy of the New Barrett TAL Formula With the Argos Measurements: A Multicenter Prospective Study

Treating Low-Income Smokers in the Hospital Emergency Department

Study of Oral Ixazomib in Adult Participants With Relapsed or Refractory Light Chain Amyloidosis

A Pilot Study of Changing Medication Adherence In Hypertensive African-American Patients

Safety and Immunogenicity of Various Formulations of Live Attenuated Tetravalent Dengue Vaccine in Healthy US Adults

A Study of the Safety and Efficacy Interferon-Gamma 1b in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Dose Escalation and Remission (DEAR)